1	SENATE FLOOR VERSION
2	March 24, 2021  AS AMENDED
3	ENGROSSED HOUSE
4	BILL NO. 2510 By: Kannady of the House
5	and
6	Thompson of the Senate
7	
8	An Act relating to opioid abatement; amending Sections 3 and 6, Chapter 130, O.S.L. 2020 (74 O.S.
9	Supp. 2020, Sections 30.5 and 30.8), which relate to the Political Subdivisions Opioid Abatement Grants
10	Act; modifying scope of certain defined terms; revising criteria for allocating opioid grant awards
11	to eligible participants; eliminating requirement for legal services agreements; requiring initial opioid
12	grant awards to be listed on a distribution table;
13	and declaring an emergency.
14	
15	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
16	SECTION 1. AMENDATORY Section 3, Chapter 130, O.S.L.
17	2020 (74 O.S. Supp. 2020, Section 30.5), is amended to read as
18	follows:
19	Section 30.5. As used in the Political Subdivisions Opioid
20	Abatement Grants Act:
21	1. "Approved purpose" and "approved purposes" mean evidence-
22	based, forward-looking strategies, programming and services used to:
23	
24	

1	a.	expand the availability of treatment for individuals
2		affected by opioid use disorders, co-occurring
3		substance use disorders and mental health issues,
4	b.	develop, promote and provide evidence-based opioid use
5		prevention strategies,
6	С.	provide opioid use disorder and co-occurring substance
7		use disorder avoidance and awareness education,
8	d.	decrease the oversupply of licit and illicit opioids,
9	е.	support recovery from addiction services performed by
10		qualified and appropriately licensed providers,
11	f.	treat opioid use, abuse and disorders, including early
12		intervention screening, counseling and support,
13	g.	support individuals in treatment and recovery from
14		opioid use, abuse and disorder,
15	h.	provide programs or services to connect individuals
16		with opioid use, abuse or disorder, or who are at risk
17		of developing opioid use disorder, co-occurring
18		substance use disorder and mental health issues, with
19		treatment and counseling programs and services,
20	i.	address the needs of individuals who are involved, or
21		who are at risk of becoming involved, in the criminal
22		justice system due to opioid use, abuse or disorder
23		through programs or services in municipal and county
24		criminal judicial systems, including prearrest and

1		postarrest diversion programs, pretrial services and
2		drug or recovery courts,
3	j.	address the needs of pregnant or parenting women with
4		opioid use, abuse or disorder and their families $_{ au}$
5		including babies with neonatal abstinence syndrome,
6	k.	address the needs of parents and caregivers caring for
7		babies with neonatal abstinence syndrome,
8	<u>1.</u>	support efforts to prevent overprescribing and ensure
9		appropriate prescribing and dispensing of opioids,
10	<del>l.</del> m.	support efforts to discourage or prevent misuse of
11		opioids, including the oversupply of licit and illicit
12		opioids,
13	m. n.	support efforts to prevent or reduce overdose deaths
14		or other opioid-related harms, including through
15		increased availability and distribution of naloxone
16		and other drugs that treat overdoses for use by first
17		responders, persons who have experienced an overdose
18		event, families, schools, community-based service
19		providers, social workers and other members of the
20		public,
21	<del>n.</del> o.	reimburse or fund law enforcement and emergency
22		responder expenditures relating to the opioid
23		epidemic, including costs of responding to emergency
24		medical or police calls for service, equipment,

1		treatment or response alternatives, mental health
2		response training and training for law enforcement and
3		emergency responders as to appropriate practices and
4		precautions when dealing with opioids or individuals
5		who are at risk of opioid overdose or death,
6	<del>o.</del> <u>p.</u>	reimburse attorney fees and expenses directly related
7		to opioid litigation incurred as part of legal
8		services agreements entered into before May 21, 2020,
9	<u>q.</u>	support efforts to provide leadership, planning and
10		coordination to abate the opioid epidemic through
11		activities, programs or strategies for prevention and
12		recovery models, including regional intergovernmental
13		efforts and not-for-profit agency support,
14	<del>p.</del> <u>r.</u>	support education of youths regarding the dangers of
15		opioid use, abuse and addiction,
16	<del>q.</del> <u>s.</u>	fund training relative to any approved purpose,
17	<del>r.</del> <u>t.</u>	monitor, surveil and evaluate opioid use, abuse or
18		disorder, or
19	<del>s.</del> <u>u.</u>	provide opioid abatement as identified by the Oklahoma
20		Opioid Abatement Board as consistent with the purpose
21		of this act the Political Subdivisions Opioid
22		Abatement Grants Act.
23	Provided that	such strategies, programming and services occurred on
24	or after Janu	ary 1, <del>2006</del> 2015;

- 2. "Board" means the Oklahoma Opioid Abatement Board;
- 3. "Eligible participant" means any political subdivision or first responder organization that obtained legal representation or participated in litigation with pharmaceutical supply chain participants prior to the effective date of this act negatively impacted by the opioid crisis;
- 4. "First responder organization" means a nonprofit organization formed and in good standing under 501(c)(9) of the Internal Revenue Code, whose primary function is to benefit public safety employees;
- 5. "Nonapproved purpose" and "nonapproved purposes" mean strategies, programming and services not falling within the definition of "approved purpose" or "approved purposes" as defined in this act section;
- 6. "Opioid funds" means all monetary amounts obtained through a settlement or judgment by the Attorney General on behalf of the State of Oklahoma related to opioid litigation involving pharmaceutical supply chain participants, including the Purdue Political Subdivisions Fund but excluding all other funds received pursuant to the Purdue Settlement Agreement;
- 7. "Opioid grant awards" means grants funded from the Oklahoma Opioid Abatement Revolving Fund, awarded pursuant to the provisions of this act the Political Subdivisions Opioid Abatement Grants Act;

- 8. "Pharmaceutical supply chain" means the process and channels through which controlled substances are manufactured, marketed, promoted, distributed or dispensed;
  - 9. "Pharmaceutical supply chain participant" means any entity that engages in or has engaged in the manufacture, marketing, promotion, distribution or dispensing of an opioid analgesic;
  - 10. "Political subdivision" and "political subdivisions" have the same meaning as provided in subparagraphs a, b, c and d of paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes;
  - 11. "Purdue Political Subdivision Fund" means the Twelve
    Million Five Hundred Thousand Dollars (\$12,500,000.00) plus any
    interest accrued thereon received from the Revive Oklahoma Health
    Foundation consisting of funds from the Purdue Settlement Agreement
    designed for distribution to political subdivisions which have
    executed a release of legal claims as required by the Purdue
    Settlement Agreement; and
  - 12. "Purdue Settlement Agreement" means the settlement agreement entered into by the State of Oklahoma and Purdue Pharma L.P., Purdue Pharma, Inc. and the Purdue Frederick Company on March 26, 2019, and approved by the Court on April 2, 2019.
- 21 SECTION 2. AMENDATORY Section 6, Chapter 130, O.S.L.
- 22 2020 (74 O.S. Supp. 2020, Section 30.8), is amended to read as
- 23 follows:

1	Section 30.8. A. 1. The Oklahoma Opioid Abatement Board shall
2	conduct an initial disbursement of opioid grant awards to
3	participating eligible participants. Such opioid grant awards shall
4	be allocated amongst the different participating eligible
5	participants based on <del>the following</del> criteria <del>, giving equal weight to</del>
6	each criteria:
7	a. the number of people per capita suffering from opioid

- the number of people per capita suffering from opioid
  use disorder in the participating political
  subdivision, or in the absence of such information,
  the opioid prescription rate in the political
  subdivision compared to the national average opioid
  prescription rate,
- b. the number of opioid overdose deaths in the participating political subdivision, and
- c. the amount of opioids distributed within the

  participating political subdivision adopted by the

  Board.
- 2. Grant awards shall be subject to legal services agreements entered into by participating eligible participants based on the grant awards.
- 3. Initial opioid grant awards as provided for in this subsection shall be listed in an opioid grant award allocation matrix distribution table reviewed and approved by the Board to

1 ensure that such awards adhere to the criteria as provided in this 2 subsection adopted by the Board. 3 B. Following the awarding of opioid grant awards pursuant to subsection A of this section, any remaining unencumbered balance in 4 5 the Oklahoma Opioid Abatement Revolving Fund shall be available to the Board to award as grants to eligible participants; provided such 6 7 awards shall only be utilized by eligible participants for approved purposes. 9 C. In the event an eligible participant merges, dissolves or ceases to exist, any remaining allocations of an awarded opioid 10 11 grant award in excess of Five Hundred Dollars (\$500.00) shall be 12 reallocated equitably based on the composition of the successor eligible participant or the successor eligible participants. 13 SECTION 3. It being immediately necessary for the preservation 14 of the public peace, health or safety, an emergency is hereby 15 declared to exist, by reason whereof this act shall take effect and 16 be in full force from and after its passage and approval. 17 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS 18 March 24, 2021 - DO PASS AS AMENDED 19 20 21 22 23 24